Valuation: AbbVie Inc.

Market Cap 435B 376B 351B 322B 606B 41,379B 616B 4,121B 1,617B 20,740B 1,633B 1,597B 68,566B P/E 2026 *
32.4x
P/E 2027 * 23.4x
Enterprise Value 497B 430B 402B 369B 693B 47,333B 704B 4,713B 1,850B 23,725B 1,868B 1,827B 78,432B EV / Sales 2026 *
7.35x
EV / Sales 2027 * 6.65x
Free-Float
95.71%
Yield 2026 *
2.81%
Yield 2027 * 2.94%
1 day+0.89%
1 week-1.95%
Current month-1.95%
1 month-2.65%
3 months+22.07%
6 months+10.12%
Current year+7.68%
1 week 241.2
Extreme 241.2
256.2
1 month 241.2
Extreme 241.2
267.47
Current year 190.75
Extreme 190.75
267.47
1 year 190.75
Extreme 190.75
267.47
3 years 135.85
Extreme 135.85
267.47
5 years 105.56
Extreme 105.56
267.47
10 years 55.06
Extreme 55.0623
267.47
Manager TitleAgeSince
Chief Executive Officer 55 01/07/2024
Director of Finance/CFO 59 23/06/2022
Chief Tech/Sci/R&D Officer - 01/03/2024
Director TitleAgeSince
Director/Board Member 65 01/01/2013
Director/Board Member 74 01/01/2013
Director/Board Member 69 01/01/2013
Date Insider Type Main position Quantity % Market Cap.
30/06/26 Free

Director

62 0.0000%
30/06/26 Free

Director

134 0.0000%
08/05/26 Free

Director

1,118 0.0001%
Change 5-day change 1-year change 3-year change Capi.($)
+0.89%-1.95%+24.23%+64.44% 435B
-0.52%+3.21%+89.52%+127.32% 1,057B
+0.88%+1.13%+49.56%+49.69% 625B
+0.71%+3.87%+49.07%+37.85% 363B
+0.64%-0.49%+33.94%+40.01% 296B
+0.39%-5.83%+8.92%+7.85% 249B
+1.51%+6.69%+42.58%+57.57% 222B
+3.92%-0.46%-5.56%-52.32% 209B
+1.80%+2.30%+11.56%+66.35% 165B
+2.14%+7.00%+8.87%-24.92% 153B
Average +1.24%+1.30%+31.27%+37.38% 377.33B
Weighted average by Cap. +0.72%+1.38%+47.11%+61.01%

Financials

2026 *2027 *
Net sales 67.62B 58.49B 54.62B 50.11B 94.25B 6,436B 95.75B 641B 252B 3,226B 254B 248B 10,664B 73.64B 63.7B 59.49B 54.57B 103B 7,009B 104B 698B 274B 3,513B 277B 270B 11,613B
Net income 13.85B 11.98B 11.19B 10.26B 19.31B 1,318B 19.61B 131B 51.53B 661B 52.02B 50.88B 2,185B 18.9B 16.35B 15.27B 14.01B 26.34B 1,799B 26.76B 179B 70.31B 902B 70.98B 69.42B 2,981B
Net Debt 62.56B 54.12B 50.54B 46.36B 87.2B 5,954B 88.58B 593B 233B 2,984B 235B 230B 9,866B 55.04B 47.61B 44.46B 40.78B 76.71B 5,238B 77.92B 522B 205B 2,625B 207B 202B 8,679B
Logo AbbVie Inc.
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
57,000
Date Price Change Volume
07/08/26 $246.04 +0.89% 4,930,711
06/08/26 $243.87 -0.95% 4,570,167
05/08/26 $246.20 +0.98% 5,193,732
04/08/26 $243.80 -0.53% 8,028,831
03/08/26 $245.10 -2.33% 7,435,935
Trader
Investor
Global
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
31
Last Close Price
246.04USD
Average target price
274.36USD
Spread / Average Target
+11.51%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ABBV Stock